About iGenomX
iGenomX is a Healthcare company based in San Diego (United States) founded in 2012, and was acquired by Twist Bioscience in June 2021. NGS library construction solutions are provided to enhance DNA sequencing. iGenomX has raised $5.13 million across 2 funding rounds from investors including Twist Bioscience. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is IGENOMX INTERNATIONAL GENOMICS CORPORATION. Its competitors include GenScript, RareCyte and Sequenta; 3 of its 3 listed competitors have raised funding.
Company details
iGenomX offers low-cost sample preparation technology capable of detecting all genetic variation. The tech was licensed from the laboratory of Dr. Daniel Salomon at the Scripps Research Institute. The low cost, fully automatable methodology centers around precisely controlling the polymerase enzyme to catalyze the formation of long-chain molecules by linking smaller molecular units, such as nucleotides with nucleic acids. This overcomes uncontrolled polymerization which causes amplification bias and error propagation, which leads to increased costs and reduced data quality.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website igenomx.com
- Acquired by Twist Bioscience (Jun 2021)
- Legal Name Igenomx International Genomics Corporation
- Total Equity Funding$5.13M (USD)
in 2 rounds
- Latest Funding Round$2.11M (USD), Series A
Apr 2019
- Investors
- Acquired byTwist Bioscience
(Jun 2021)
Funding Insights of iGenomX
iGenomX has successfully raised a total of $5.13M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.11 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.13M
- Total Rounds 2
- Last Round Series A — $2.11M
- First Round $3.02M
(Dec 2015)
All 2 funding rounds of iGenomX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $2.11M | Series A | – | – | – |
| Dec 2015 | $3.02M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in iGenomX
iGenomX has secured backing from 1 investor. Prominent investors backing the company include Twist Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Synthetic DNA is synthesized via a semiconductor-based platform. | 2013 | twistbioscience.com | San Francisco, United States |
Investor details for iGenomX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of iGenomX
4 dated milestones of iGenomX across 9 years, from founding to its latest funding, stage changes and deals.
- Founded iGenomX is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series A, of $2.1M.
- Exit Acquired by Twist Bioscience.
Competitors of iGenomX
iGenomX has 3 listed competitors in our database, 3 of them funded. They include GenScript, RareCyte and Sequenta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. |
Detailed competitors of iGenomX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as iGenomX (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Igenomx
Complete news archive for iGenomX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iGenomX
iGenomX was founded in 2012 and raised its 1st funding round 3 years after it was founded.
iGenomX is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
iGenomX is a funded company, having raised a total of $5.13M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.02M, raised on Dec 2015.
iGenomX offers low-cost sample preparation technology capable of detecting all genetic variation. The tech was licensed from the laboratory of Dr. Daniel Salomon at the Scripps Research Institute. The low cost, fully automatable methodology centers around precisely controlling the polymerase enzyme to catalyze the formation of long-chain molecules by linking smaller molecular units, such as nucleotides with nucleic acids. This overcomes uncontrolled polymerization which causes amplification bias and error propagation, which leads to increased costs and reduced data quality.
iGenomX has 1 investor. Key investors include Twist Bioscience.
iGenomX operates through Igenomx International Genomics Corporation.
Yes. iGenomX was acquired by Twist Bioscience in June 2021.